Clotting disorders anticoagulants

Drugs used in clotting disorders Clot reducers Anticoagulants Antiplatelet agents Thrombolytics Clot facilitators... 

In general, the Factor VII activity estimated by a substrate assay correlated well with Factor VII activity determined by a clot-endpoint assay (P4, S13). However, some differences have been seen. Activation of Factor VII by kaolin or by exposure to cold temperatures (2-8°C) increased the level of clotting Factor VII by 4-7 times but bad no effect on the amount detected by the substrate assay (S9, TIO). It has been postulated that the partially carbox-ylated molecules of Factor VII present in patients plasma during anticoagulant therapy are detected by a substrate assay but not in a clot-endpoint test (P4). These differences between the two assay systems have been used to screen for hereditary Factor VII deficients and to detect the presence of Factor Vila in thrombotic disorders and in components for transfusion therapy (S13). 

Circulatory disorders impair the flow of blood throughout the body. Circulatory dmgs are used to restore and maintain circulation. There are four groups of circulatory dmgs anticoagulants and antiplatelets prevent blood clots from forming, thrombolytics dissolve blood clots, antihpemics decrease blood lipids, and peripheral vasodilators dilate vessels narrowed by vasospasm. 

---